---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-052454"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:44:51.444702+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics implements 1-for-40 reverse stock split to meet Nasdaq minimum bid requirement

## Summary
- Reverse stock split effective 4:05 pm NY time June 28, 2023 at a 1-for-40 ratio.
- Outstanding shares reduced from 20,142,633 to approximately 503,566; fractional shares rounded up.
- Split intended to increase per-share price and bring company into compliance with Nasdaq minimum bid price.
- Common stock begins trading on post-split basis under symbol ALLR on June 29, 2023.

## SEC filing metadata
- accession: 0001213900-23-052454
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023052454/0001213900-23-052454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023052454/ea180985-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-052454
- JSON: https://secwatch.observer/filing/0001213900-23-052454.json
- Plain text: https://secwatch.observer/filing/0001213900-23-052454.txt

## Key facts
- Governance Changes
  Allarity Therapeutics, Inc.: Filed Fourth Certificate of Amendment to effect a 1-for-40 reverse stock split of common stock (effective 2023-06-28).
  - Change: charter amendment
  - Effective: 2023-06-28
  source text: On June 28, 2023, upon receipt of the required stockholder approval, Allarity Therapeutics, Inc. (the “Company”) filed a Fourth Certificate of Amendment of Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-40 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 4:05 p.m. (New York time) on June 28, 2023 (the “Reverse Stock Split”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023052454/0001213900-23-052454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.